Diagenode Launches Extensively Validated Epigenetic Antibodies for Broad Research Use
Industry’s most highly validated antibodies as used by the BLUEPRINT Epigenome Consortium researchers are now broadly available for epigenetics researchers worldwide.
Diagenode, Inc., a leading global provider of complete solutions for epigenetics research, recently launched its “Premium” line of antibodies for epigenetics applications such as chromatin immunoprecipitation (ChIP) and DNA methylation. These antibodies have been extensively validated for high sensitivity and specificity through a multi-step process including assessment through ELISA, dot blot, peptide arrays, Western blot, IF, CHIP-qPCR, and ChIP-seq. They were initially developed in a collaborative effort for the well-known BLUEPRINT Epigenome consortium and now have been released for widespread research use.
